Drug Profile
Clonidine sustained release - Tris Pharma
Alternative Names: Nexiclon XRLatest Information Update: 07 Mar 2022
Price :
$50
*
At a glance
- Originator Tris Pharma
- Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Behavioural disorder therapies; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 03 Mar 2022 Athena Biosciences plans to launch clonidine extended-release tablets for Hypertension in USA in April 2022
- 03 Mar 2022 US FDA approves the supplemental NDA (sNDA) for the treatment of hypertension in USA prior to March 2022
- 22 Feb 2021 Clonidine licensed to Athena Bioscience for the treatment of hypertension in the US